Table 4.
List of small molecule inhibitors for viral RNA MTases. The ‘design strategy’ column describes the basic method for inhibitor design, while ‘evaluation method’ roughly lists the experiments conducted in the associated references. CADD = computer aided drug design, i.s. = in silico; i.vt. = in vitro; i.c. = in cellulo; i.vv. = in vivo
| Organism | Enzyme/modification/RNA species | Design strategy | Evaluation method | References |
|---|---|---|---|---|
| dengue virus (DENV) | NS5/ m7G/ mRNA cap | CADD | i.vt. | (301) |
| i.s., i.vt. | (302) | |||
| i.vt., i.c. | (303) | |||
| SAH analogue | i.vt. | (248) | ||
| i.vt., i.c. | (304) | |||
| LTS | i.vt. | (305) | ||
| FBDD | i.vt. | (249) | ||
| i.s., i.vt., i.c. | (250) | |||
| NS5/ 2′-O/ mRNA cap | CADD | i.vt. | (301) | |
| i.s., i.vt. | (302,306) | |||
| i.vt., i.c. | (303) | |||
| i.s., i.vt., i.c. | (143) | |||
| Nucleotide analogue | i.vt | (307) | ||
| i.vt. | (308) | |||
| i.s., i.vt., i.c | (309) | |||
| SAH analogue | i.vt., i.c. | (304) | ||
| i.vt. | (248,310) | |||
| LTS | i.vt. | (305) | ||
| FBDD | i.vt. | (249,251) | ||
| i.vt., i.c. | (252) | |||
| i.s., i.vt., i.c. | (250) | |||
| not determined | CADD | i.s. | (311–315,323) | |
| i.vt., i.c. | (316) | |||
| Nucleotide analogue | i.vt., i.c. | (317) | ||
| LTS | i.s., i.c., i.vv. | (318) | ||
| HTS | i.vt. | (319) | ||
| zika virus (ZIKV) | NS5/ 2′-O/ mRNA cap | Nucleotide analogue | i.s., i.vt.,i.c. | (309) |
| FBDD | i.vt. | (251) | ||
| i.s., i.vt., i.c. | (252) | |||
| not determined | CADD | i.s. | (320–322) | |
| i.s., i.c. | (324) | |||
| i.s., i.vt. i.c. | (316) | |||
| SAH analogue | i.s., i.vt. | (325) | ||
| i.c. | (326) | |||
| HTS | i.s., i.vt.,i.c. | (327) | ||
| west nile virus (WNV) | NS5/ m7G/ mRNA cap | CADD | i.vt.,i.c. | (302) |
| i.s., i.vt.,i.c. | (303) | |||
| Nucleotide analogue | i.s., i.vt.,i.c. | (328) | ||
| SAH analogue | i.s., i.vt.,i.c. | (304) | ||
| HTS | i.vt., i.c. | (329) | ||
| NS5/ 2′-O/ mRNA cap | CADD | i.vt.,i.c. | (302) | |
| i.s., i.vt.,i.c. | (303) | |||
| Nucleotide analogue | i.s., i.vt.,i.c. | (328) | ||
| SAH analogue | i.s., i.vt.,i.c. | (304) | ||
| FBDD | i.vt. | (250) | ||
| not determined | Nucleotide analogue | i.s., i.c. | (317) | |
| yellow fever virus (YFV) | NS5/ m7G/ mRNA cap | CADD | i.vt. | (302,303) |
| SAH analogue | i.v., i.c. | (304) | ||
| NS5/ 2′-O/ mRNA cap | CADD | i.vt. | (302,303) | |
| SAH analogue | i.v., i.c. | (304) | ||
| Nucleotide analogue | i.s., i.c. | (309) | ||
| not determined | HTS | i.vt. | (330) | |
| i.s., i.vt. | (319) | |||
| wesselbron virus (WV) | NS5/ m7G/ mRNA cap | CADD | i.s., i.v. | (301) |
| NS5/ 2′-O/ mRNA cap | CADD | i.s., i.v. | (301) | |
| japanese encephalitis virus (JEV) | not determined | CADD | i.c. | (303) |
| St. louis encephalitis virus (SLEV) | not determined | CADD | i.c. | (303) |
| severe acute respiratory syndrome coronavirus (SARS-CoV) | nsp14/ m7G/ mRNA cap | SAH analogue | i.s., i.vt. | (164) |
| LTS | i.vt. | (259) | ||
| HTS | i.vt. | (331) | ||
| i.vt., i.c. | (332) | |||
| nsp16/ 2′-O/ mRNA cap | LTS | i.vt. | (259) | |
| SARS-CoV-2 | nsp14/ m7G/ mRNA cap | CADD | i.s. | (267,333–338) |
| SAH analogue | i.s., i.vt. | (268,270) | ||
| i.s., i.vt., i.c. | (269) | |||
| HTS | i.vt. | (125) | ||
| i.vt., i.c. | (131,339) | |||
| nsp16/ 2′-O/ mRNA cap | CADD | i.s. | (267,337,338, 340–363) | |
| i.s., i.vt. | (364) | |||
| SAH analogue | i.s., i.vt., i.c. | (269) | ||
| HTS | i.vt. | (365,366) | ||
| chikungunya virus (CHIKV) | nsp1/ m7G/ mRNA cap | GTP analogue | LTP | (367) |
| nucleoside analogue | i.c. | (368) | ||
| CADD, nucleoside analogue | i.vt., i.c. | (369,370) | ||
| natural products | i.vt. | (371) | ||
| HTS | i.vt., i.c. | (372) | ||
| HTS | i.c., i.vt. | (373) |